Vectibix® (Panitumumab) Granted Approval for Expanded Indications in the European Union
Thousand Oaks, California, November 15 (ots/PRNewswire) - Amgen today announced that the European Commission (EC) has approved a variation to the marketing authorization for Vectibix(R) (panitumumab) to include indications for the treatment of patients with wild-type KRAS metastatic colorectal cancer (mCRC) in first-line in combination with FOLFOX and in second-line in ...
mehr